1. Home
  2. YEXT vs CLLS Comparison

YEXT vs CLLS Comparison

Compare YEXT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yext Inc.

YEXT

Yext Inc.

HOLD

Current Price

$4.96

Market Cap

397.0M

Sector

Technology

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$2.80

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YEXT
CLLS
Founded
2006
1999
Country
United States
France
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.0M
394.4M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
YEXT
CLLS
Price
$4.96
$2.80
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$7.50
$8.33
AVG Volume (30 Days)
1.4M
25.6K
Earning Date
06-02-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
131.82
N/A
EPS
0.02
N/A
Revenue
$170,201,000.00
N/A
Revenue This Year
$3.95
N/A
Revenue Next Year
$2.46
$0.98
P/E Ratio
$259.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.27
$2.00
52 Week High
$9.20
$5.48

Technical Indicators

Market Signals
Indicator
YEXT
CLLS
Relative Strength Index (RSI) 52.70 45.30
Support Level $4.75 $2.70
Resistance Level $5.69 $3.40
Average True Range (ATR) 0.23 0.13
MACD -0.03 -0.01
Stochastic Oscillator 19.91 32.50

Price Performance

Historical Comparison
YEXT
CLLS

About YEXT Yext Inc.

Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: